GlassScriptPhysician profile
David M Rankin
NPI 1225027865
$5,858.21
in general payments reported to CMS, 2019-2025
33 companies · $778 in 2025
The $778 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $657 · 2020: $409 · 2021: $563 · 2022: $936 · 2023: $1,377 · 2024: $1,138 · 2025: $778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,231 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,231.43 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,000.76 | 2019-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $810.53 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $514.89 | 2019-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $477.69 | 2019-2025 | |
| Pfizer INC. | $440.65 | 2019-2025 | |
| Lundbeck LLC | $405.32 | 2022-2024 | Vyepti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $318.35 | 2019-2025 | Jardiance, Ofev |
| Abbvie INC. | $283.95 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $226.26 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $209.56 | 2023-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $205.20 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $94.78 | 2022 | |
| Exact Sciences Corporation | $76.28 | 2025 | Cologuard Collection Kit |
| Allergan, INC. | $71.76 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $67.67 | 2020-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.36 | 2021-2023 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $56.32 | 2024-2025 | Caplyta |
| Glaxosmithkline, LLC. | $54.20 | 2022-2024 | Trelegy Ellipta, Shingrix, Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $51.91 | 2019 | |
| Sumitomo Pharma America, INC. | $49.63 | 2023-2024 | Gemtesa |
| Regeneron Healthcare Solutions, INC. | $46.55 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $44.58 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $41.60 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $37.70 | 2019-2020 | |
| Daiichi Sankyo INC. | $34.45 | 2019-2020 | |
| Intra-Sana Laboratories | $33.43 | 2023 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Ironwood Pharmaceuticals, INC | $31.41 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $28.47 | 2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $24.01 | 2025 | Gvoke Hypopen |
| Genentech USA, INC. | $22.33 | 2020 | |
| Alexion Pharmaceuticals, INC. | $13.67 | 2022 | |
| Endogastric Solutions, INC | $13.13 | 2023 | Esophyx |
| Aytu Biopharma, INC. | $12.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rankin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.